Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multifocal calcific periarthritis with distinctive clinical and radiological features in patients with CD73 deficiency.
Cudrici CD, Newman KA, Ferrante EA, Huffstutler R, Carney K, Betancourt B, Miettinen M, Siegel R, Katz JD, Nesti LJ, St Hilaire C, Lakshmipathy D, Wen H, Bagheri MH, Boehm M, Brofferio A. Cudrici CD, et al. Rheumatology (Oxford). 2021 Dec 24;61(1):163-173. doi: 10.1093/rheumatology/keab270. Rheumatology (Oxford). 2021. PMID: 33744914 Free PMC article.
Intralesional administration of epidermal growth factor-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure.
Fernández-Montequín JI, Betancourt BY, Leyva-Gonzalez G, Mola EL, Galán-Naranjo K, Ramírez-Navas M, Bermúdez-Rojas S, Rosales F, García-Iglesias E, Berlanga-Acosta J, Silva-Rodriguez R, Garcia-Siverio M, Martinez LH. Fernández-Montequín JI, et al. Among authors: betancourt by. Int Wound J. 2009 Feb;6(1):67-72. doi: 10.1111/j.1742-481X.2008.00561.x. Int Wound J. 2009. PMID: 19291119 Free PMC article. Clinical Trial.
Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.
Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA; Cuban Citoprot-P Study Group. Fernández-Montequín JI, et al. Among authors: betancourt by. Int Wound J. 2007 Dec;4(4):333-43. doi: 10.1111/j.1742-481X.2007.00344.x. Epub 2007 Oct 22. Int Wound J. 2007. PMID: 17953679 Free PMC article. Clinical Trial.
Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients.
Cáceres-Lóriga FM, Pérez-López H, Morlans-Hernández K, Facundo-Sánchez H, Santos-Gracia J, Valiente-Mustelier J, Rodiles-Aldana F, Marrero-Mirayaga MA, Betancourt BY, López-Saura P. Cáceres-Lóriga FM, et al. Among authors: betancourt by. J Thromb Thrombolysis. 2006 Apr;21(2):185-90. doi: 10.1007/s11239-006-4969-y. J Thromb Thrombolysis. 2006. PMID: 16622616 Review.
Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction.
Betancourt BY, Marrero-Miragaya MA, Jiménez-López G, Valenzuela-Silva C, García-Iglesias E, Hernández-Bernal F, Debesa-García F, González-López T, Alvarez-Falcón L, López-Saura PA; Cuban National Network of Pharmacoepidemiology. Betancourt BY, et al. BMC Clin Pharmacol. 2005 Nov 2;5:5. doi: 10.1186/1472-6904-5-5. BMC Clin Pharmacol. 2005. PMID: 16262910 Free PMC article.
13 results